Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development. (3rd July 2021)

• Record Type: Journal Article
• Authors: De Lorenzo, Stefania; Garajova, Ingrid; Stefanini, Bernardo; Tovoli, Francesco
• Is Part Of: Expert opinion on investigational drugs. Volume 30:Number 7(2021)
• Page Start: 759
• Page End: 772
• Publication Date: 2021-07-03
• Subjects: Biliary tract cancer -- braf -- clinical trials -- epidermal growth factor -- gallbladder -- gallbladder cancer -- her -- immunotherapy -- outcome -- tyrosine kinase inhibitors; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2021.1928636
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Gallbladder cancer (GC) is a rare malignancy with a dismal prognosis. When diagnosed early enough, it can be cured by surgical removal. Unfortunately, only few GC patients can be amenable to surgery, though, with a high relapse rate. Conventional chemotherapy remains the golden standard for unresectable or metastatic GC, both in the first and second-line settings, even if leading to a fair outcome improvement. Areas covered : In recent years, according to the concept of 'precision medicine', new potential molecular targets have been examined. We provided a general outline of the current first- and second-line chemotherapies. New therapeutic possibilities are also reviewed, particularly HER2, EGFR, VEGF, TKI, MEK and BRAF inhibitors, and immunotherapy. Furthermore, published clinical trials are utilized to analyze the principal drug effectiveness in GC. Expert opinion : GC is characterized by vast cancer heterogeneity and individual's efficacy to different drugs. The ongoing trials have the potentiality of reshaping the landscape of systemic treatments for GC in the very next years. Nowadays, amongst therapeutic combinations, the addition of ICIs to chemotherapy has yielded encouraging results needing confirmation. In the next future, systematic implementation of gene profiling and further explorations of combination therapies will likely change the treatment scenario.